Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

Abstract Background In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. Me...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri, James Larkin
Format: Article
Language:English
Published: BMC 2018-12-01
Subjects:
Axitinib
Cabozantinib
Everolimus
Indirect comparison
Matching-adjusted comparison
mRCC
Online Access:http://link.springer.com/article/10.1186/s12885-018-5157-0

Internet

http://link.springer.com/article/10.1186/s12885-018-5157-0

Similar Items